IPCALAB
Ipca Laboratories Limited
Each stock's 10,000-path forecast, rendered as light.
Ipca Laboratories Limited (IPCALAB) Stock Analysis & Case Study
Is IPCALAB a good buy? The data-driven verdict.
Ipca Laboratories Limited (IPCALAB) trades at ₹1,736,on the numbers it worth a closer look, a Downstox Snapshot Score of 55/100.
On the numbers, Ipca Laboratories Limited (IPCALAB) worth a closer look, a Downstox Snapshot Score of 55/100, weighing premium at 37.4× earnings, ROE of 15.7%, a 61% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
IPCALAB fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How IPCALAB ranks against the 2,373 companies in our screener
- IPCALAB's market cap of 44,038 Cr ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- IPCALAB's book value of ₹318 ranks in the 82nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- IPCALAB's promoter holding of 44.7% ranks in the 22nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- IPCALAB's 3-year profit (PAT) growth of 37.0% ranks in the 76th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- IPCALAB's 3-year revenue growth of 16.0% ranks in the 65th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- IPCALAB's debt-to-equity ratio of 0.10x is lower than 77% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is IPCALAB overvalued? IPCALAB P/E vs peers
IPCALAB trades at 37.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
IPCALAB share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of IPCALAB history (20%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| IPCALAB 2027 | ₹1,269 | ₹1,890 | ₹2,815 | +9% |
| IPCALAB 2028 | ₹1,174 | ₹2,058 | ₹3,611 | +19% |
| IPCALAB 2029 | ₹1,132 | ₹2,242 | ₹4,438 | +29% |
| IPCALAB 2030 | ₹1,107 | ₹2,441 | ₹5,381 | +41% |
| IPCALAB 2031 | ₹1,108 | ₹2,658 | ₹6,377 | +53% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability IPCALAB goes up, or doubles?
The bull case for IPCALAB
- IPCALAB's return on equity of 15.7% ranks in the 74th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A 10,000-path probability model puts a 61% chance the price is higher in a year, with a median target of ₹1,890 (+9%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹4,438.
The bear case & risks
- IPCALAB's P/E of 37.4x is lower than 36% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,132.
IPCALAB volatility & expected range, how bumpy is the ride?
Over the last 9.8 years IPCALAB compounded at 20%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹1,269-₹2,815, the honest backbone behind any single price target.
IPCALAB price forecast, the full 60-month probability fan
IPCALAB price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds IPCALAB hits common targets within the simulated horizon?
Full multi-horizon detail on the IPCALAB price target & forecast page.
IPCALAB Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. IPCALAB scores 6/8, mixed financial health.
IPCALAB MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy IPCALAB with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 29.35% | 3.4× |
| Zerodha | 29.32% | 3.4× |
| Groww | 29.36% | 3.4× |
| Dhan | 29.32% | 3.4× |
| Kotak Neo | 30.03% | 3.3× |
| Paytm Money | 29.38% | 3.4× |
| Pocketful | 29.44% | 3.4× |
| Fyers | 30.30% | 3.3× |
| Anand Rathi | 29.32% | 3.4× |
| Bajaj Broking | 31.00% | 3.2× |
| Share IndiaCHEAPEST | 29.24% | 3.4× |
Compare every broker on the IPCALAB MTF page.
About Ipca Laboratories Limited: sector, index & market-cap context
Ipca Laboratories Limited (IPCALAB) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹44,038 Cr. See more stocks on our screener.
How the IPCALAB Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Ipca Laboratories Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
IPCALAB analysis, FAQs
Is Ipca Laboratories Limited (IPCALAB) a good buy?
On the numbers, Ipca Laboratories Limited (IPCALAB) worth a closer look, a Downstox Snapshot Score of 55/100, weighing premium at 37.4× earnings, ROE of 15.7%, a 61% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is IPCALAB overvalued or undervalued?
IPCALAB trades at 37.4× earnings, premium versus the ~22× long-run Nifty average.
What is the IPCALAB share price target for 2031?
IPCALAB's probability-weighted 2031 median target is ₹2,658, with an 80% range of ₹1,108-₹6,377 (10,000-path Monte-Carlo).
What is the probability IPCALAB doubles in 5 years?
The modelled probability of IPCALAB reaching ₹3,472 (2×) within 5 years is 35%.
What is the bull case for IPCALAB?
IPCALAB's return on equity of 15.7% ranks in the 74th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A 10,000-path probability model puts a 61% chance the price is higher in a year, with a median target of ₹1,890 (+9%).
What are the risks in IPCALAB?
IPCALAB's P/E of 37.4x is lower than 36% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.